Table 3.

Correlates of response to first HCC treatment

	Univariate (n=594)†		Multivariable (n=591)
Variable	OR	95% CI	aOR	95% CI
Female sex	1.57	1.13 – 2.18	1.72	1.18 – 2.53
Age	1.01	0.99 – 1.03	0.99	0.97 – 1.01
Race/ethnicity
White	Ref	Ref	Ref	Ref
Black	0.75	0.53 – 1.08	0.86	0.57 – 1.33
Hispanic	0.82	0.57 – 1.19	0.89	0.58 – 1.35
Asian	0.91	0.44 – 3.45	1.07	0.46 – 2.45
Liver disease etiology
Viral	Ref	Ref
Non-viral	1.23	0.89 – 1.70
AFP (ng/mL), n (%)
<20	Ref	Ref	Ref	Ref
20–200	0.51	0.36 – 0.73	0.56	0.38 – 0.83
>200	0.20	0.13 – 0.29	0.34	0.21 – 0.54
Child Pugh
A	Ref	Ref	Ref	Ref
B/C	0.59	0.44 – 0.80	0.76	0.52 – 1.10
BCLC stage
0/A	Ref	Ref	Ref	Ref
B	0.30	0.19 – 0.47	0.29	0.19 – 0.45
C	0.05	0.03 – 0.09	0.15	0.07 – 0.32
D	0.49	0.25 – 0.95	0.65	0.30 – 1.43
First HCC treatment
Surgical	Ref	Ref	Ref	Ref
Locoregional treatment	0.08	0.05 – 0.14	0.08	0.05 – 0.15
Systemic therapy	0.01	0.003 – 0.01	0.02	0.01 – 0.05

^†Results from ordinal logistic regression model comparing complete response vs partial response vs stable disease vs progressive disease, in the subset of patients with available imaging assessment to 1^st HCC treatment (n=597 of 752 treated patients). AFP – alpha-fetoprotein; BCLC - Barcelona Clinic Liver Cancer; HCC – hepatocellular carcinoma; OR – odds ratio